Hoffmann-la Roche

This early-stage study tests a new drug (RO7673396) in people with advanced solid tumors that have RAS mutations and haven't responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors when given alone or …

This study tests a new medicine called NXT007 against an existing drug, emicizumab, to see which better prevents bleeding episodes in people with hemophilia A. The trial includes 360 participants aged 12 and older with severe or moderate hemophilia A, with or without inhibitors. …

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. Researchers are testing a drug called mosunetuzumab, either alone or combined with another drug (venetoclax), to see if they are safe and …

This study looks at the long-term safety of astegolimab in people with chronic obstructive pulmonary disease (COPD). Participants must have already completed a one-year treatment period in a previous study. The main goal is to track any side effects over an extended time.

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About …

This study tests an experimental drug called fenebrutinib in 12 children and teens (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions, and if it is safe. Participants can choose to continue …

This early-stage study tests a new drug called RO7812653 in about 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side eff…